Changing Dynamics of COVID-19 in the U.S. with the Emergence of the Delta Variant: Projections of the COVID-19 Simulator
Chhatwal, J.; Xiao, Y.; Mueller, P. C. P.; Ayer, T.; Adee, M. G.; Dalgic, O.; Ladd, M. A.; Linas, B.
Show abstract
With the recent emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2 in the U.S., many states are seeing rising cases and hospitalizations after a period of steady decline. As We used the COVID-19 Simulator, an interactive online tool that utilizes a validated mathematical model, to simulate the trajectory of COVID-19 at the state level in the U.S. COVID-19 Simulators forecasts are updated weekly and included in the Centers for Disease Control and Prevention (CDC) ensemble model. We employed our model to analyze scenarios where the Delta variant becomes dominant in every state. The combination of high transmissibility of the Delta variant, low vaccination coverage in several regions, and more relaxed attitude towards social distancing is expected to result in as surge in COVID-19 deaths in at least 40 states. In several states - including Idaho, Maine, Montana, Nebraska, North Carolina, Oregon, Puerto Rico, Washington, and West Virginia - the projected daily deaths in 2021 could exceed the prior peak daily deaths under current social distancing behavior and vaccination rate. The number of COVID-19 deaths across the U.S. could exceed 1600 per day. Between August 1, 2021, and December 31, 2021, there could be additional 157,000 COVID-19 deaths across the U.S. Of note, our model projected approximately 20,700 COVID-19 deaths in Texas, 16,000 in California, 12,400 in Florida, 12,000 in North Carolina, and 9,300 in Georgia during this period. In contrast, the projected number of COVID-19 deaths would remain below 200 in New Jersey, Massachusetts, Connecticut, Vermont, and Rhode Island. We project COVID-19 deaths based on the current vaccination rates and social distancing behavior. Our hope is that the findings of this report serve a warning sign and people revert to wearing masks and maintain social distancing to reduce COVID-19 associated deaths in the U.S. Our projections are updated weekly by incorporating vaccination rates and social distancing measures in each state; the latest results can be found at the COVID-19 Simulator website.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The Epidemiological Implications of Jails for Community, Corrections Officer, and Incarcerated Population Risks from COVID-19 94%
- Use of recently vaccinated individuals to detect bias in test-negative case-control studies of COVID-19 vaccine effectiveness 93%
- Theoretical framework for retrospective studies of the effectiveness of SARS-CoV-2 vaccines 93%
Similar papers in this journal
- The Joint Impact of COVID-19 Vaccination and Non-Pharmaceutical Interventions on Infections, Hospitalizations, and Mortality: An Agent-Based Simulation 97%
- Identifying silent COVID-19 infections among children is critical for controlling the pandemic 95%
- Estimation of COVID-19 cases prevented by vaccination in California 94%
Similar papers in this journal
- Lives saved and hospitalizations averted by COVID-19 vaccination in New York City 95%
- Impact of SARS-CoV-2 vaccination of children ages 5-11 years on COVID-19 disease burden and resilience to new variants in the United States, November 2021-March 2022: a multi-model study 93%
- Time-Varying Effectiveness of Three Covid-19 Vaccines in Puerto Rico 93%
Similar papers in this journal
- COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact 95%
- The Balancing Role of Distribution Speed against Varying Efficacy Levels of COVID-19 Vaccines under Variants 95%
- Continued need for non-pharmaceutical interventions after COVID-19 vaccination in long-term-care facilities 93%
Similar papers in this journal
- Using LASSO regression to estimate the population-level impact of pneumococcal conjugate vaccines 94%
- Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel 94%
- Estimating protection afforded by prior infection in preventing reinfection: Applying the test-negative study design 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.